Evolent Health, Inc.EVHNYSE

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 89% recommend buying.

Consensus Rating

Buy

27 analysts·High coverage

89%

Rating Distribution

Strong Buy

00%

Buy

2489%

Hold

311%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 135% higher.

Bear Case

$6.00

+76%

Consensus

$8.00

+135%

Bull Case

$10.00

+194%

Price Range27 analysts

Low

Consensus

High

$6.00

$10.00

Current Target

Current Price

$3.40

Upside to Target

$4.60

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$0.31(6 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+12.59%

EPS+69.11%

FY2028

Rev+16.03%

EPS+43.87%

FY2029

Rev+13.23%

EPS+28.00%

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:+10.3%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Feb 2, 2026BTIG

Evolent Health price target lowered to $10 from $16 at BTIG

Target:$10.00

+211.5%from $3.21

Dec 2, 2025Piper Sandler

Evolent Health (EVH) PT Lowered to $6 at Piper SandlerMember Login

Target:$6.00

+56.5%from $3.83

Jan 16, 2025UBS

Evolent Health price target lowered to $14 from $27 at UBS

Target:$14.00

+40.4%from $9.97

Jan 15, 2025Truist Financial

Evolent dips after Truist warns guidance may be 'significantly' below consensus

Target:$20.00

+100.6%from $9.97

Jan 14, 2025RBC Capital

Evolent Health (EVH) PT Lowered to $17 at RBC Capital as Membership Declines

Target:$17.00

+42.1%from $11.96

Jan 10, 2025JMP Securities

Evolent Health price target lowered to $18 from $27 at JMP Securities

Target:$18.00

+43.5%from $12.54

Nov 18, 2024Oppenheimer

Evolent Health (EVH) PT Lowered to $28 at Oppenheimer

Target:$28.00

+122.4%from $12.59

Oct 17, 2024Stephens

Evolent weakness linked to elevated Medicaid MLRs at peers, says Stephens

Target:$38.00

+52.3%from $24.95

Aug 9, 2024Truist Financial

Evolent Health upgraded to Buy from Hold at Truist

Target:$33.00

+58.1%from $20.87

Jun 5, 2024RBC Capital

RBC Capital Reiterates Outperform Rating on Evolent Health (EVH)

Target:$42.00

+90.6%from $22.04

May 14, 2024Truist Financial

Evolent Health (EVH) PT Lowered to $28 at Truist Securities

Target:$28.00

+17.9%from $23.75

Apr 17, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Evolent Health (EVH)

Target:$51.00

+72.3%from $29.60

Mar 28, 2024Canaccord Genuity

Evolent Health (EVH) PT Lowered to $44 at Canaccord Genuity

Target:$44.00

+34.4%from $32.73

Aug 3, 2022BTIG

BTIG Maintains Buy on Evolent Health, Raises Price Target to $50

Target:$50.00

+42.0%from $35.21

May 9, 2022Canaccord Genuity

Canaccord Genuity Maintains Buy on Evolent Health, Raises Price Target to $45

Target:$45.00

+67.2%from $26.91

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance